We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

55 hedge funds and large institutions have $15.2M invested in Galectin Therapeutics in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more call options, than puts

Call options by funds: $759K | Put options by funds: $348K

36% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 11

0.05% more ownership

Funds ownership: 12.29% → 12.35% (+0.05%)

21% less funds holding

Funds holding: 70 → 55 (-15)

46% less capital invested

Capital invested by funds: $28.2M → $15.2M (-$13.1M)

65% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 20

Holders
55
Holders Change
-15
Holders Change %
-21.43%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
15
Reduced
11
Closed
20
Calls
$759K
Puts
$348K
Net Calls
+$411K
Net Calls Change
-$1.2M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$586K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$198K
3
Millennium Management
Millennium Management
New York
+$158K
4
SF
Synovus Financial
Georgia
+$137K
5
Morgan Stanley
Morgan Stanley
New York
+$124K

Top Sellers

Rank Fund Capital Flow
1
E
Ergoteles
New York
-$529K
2
HF
HRT Financial
New York
-$311K
3
Capstone Investment Advisors
Capstone Investment Advisors
New York
-$164K
4
PPA
Parametric Portfolio Associates
Washington
-$121K
5
CF
Centaurus Financial
California
-$88K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.04M -$7.8K -2,731 -0.1%
Osaic Holdings
2
Osaic Holdings
Arizona
$2.58M -$75.8K -26,556 -2%
BlackRock
3
BlackRock
New York
$1.64M +$15.5K +5,443 +0.7%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$1.16M +$53.9K +18,862 +3%
GWM
5
Geneos Wealth Management
Colorado
$995K -$30.3K -10,600 -2%
Millennium Management
6
Millennium Management
New York
$840K +$158K +55,265 +16%
Renaissance Technologies
7
Renaissance Technologies
New York
$446K +$586K +205,304 +2,034%
CCB
8
Cutter & Co Brokerage
Missouri
$380K -$3.67K -1,285 -0.7%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$351K +$198K +69,235 +69%
State Street
10
State Street
Massachusetts
$329K – – –
Cambridge Investment Research Advisors
11
Cambridge Investment Research Advisors
Iowa
$317K -$32.8K -11,471 -7%
KeyBank National Association
12
KeyBank National Association
Ohio
$207K – – –
Northern Trust
13
Northern Trust
Illinois
$194K +$14.8K +5,168 +6%
Morgan Stanley
14
Morgan Stanley
New York
$194K +$124K +43,335 +87%
DADC
15
D.A. Davidson & Co
Montana
$114K -$5.71K -2,000 -3%
LPL Financial
16
LPL Financial
California
$99K -$5.42K -1,900 -4%
SF
17
Synovus Financial
Georgia
$99K +$137K +48,000 New
PNC Financial Services Group
18
PNC Financial Services Group
Pennsylvania
$96K – – –
AAS
19
Ameritas Advisory Services
Nebraska
$92K +$126K +44,232 New
Citadel Advisors
20
Citadel Advisors
Florida
$90K +$54.1K +18,950 +78%
SWP
21
Stratos Wealth Partners
Ohio
$85K – – –
MML Investors Services
22
MML Investors Services
Massachusetts
$70K +$8.45K +2,959 +10%
WS
23
Wedbush Securities
California
$62K -$2.85K -1,000 -3%
BFEC
24
Benjamin F. Edwards & Company
Missouri
$61K +$17.2K +6,015 +25%
HKAM
25
Horizon Kinetics Asset Management
New York
$50K – – –
1
2 3

GALT Hedge Fund Activity: Q4 2021 in Review

55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2021, worth a combined $15.2M — down 46% from $28.2M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of GALT and 7 opened new positions — a net loss of 13 holders — while 11 trimmed existing stakes and 15 added.

The largest buyer was Renaissance Technologies, adding an estimated $586K. The largest seller was Ergoteles, exiting entirely with an estimated $529K sold.

  • 55 institutional investors held Galectin Therapeutics (GALT) as of Q4 2021, down from 70 in Q3 2021.
  • Funds reported $15.2M of Galectin Therapeutics stock for Q4 2021, down 46% quarter-over-quarter.
  • 7 funds opened new Galectin Therapeutics positions in Q4 2021 and 20 closed out, a net change of -13 holders.
  • The largest Galectin Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $586K added.
  • The largest Galectin Therapeutics seller in Q4 2021 was Ergoteles, an estimated $529K sold.

Based on aggregated 13F filings for Q4 2021.